Stephanie Shiau1, Anyelina Cantos2, Christian V Ramon2, Yanhan Shen3, Jayesh Shah2, Grace Jang2, Andrea A Baccarelli4, Stephen M Arpadi3,5,6, Michael T Yin2. 1. Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ. 2. Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY. 3. Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY. 4. Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY. 5. Department of Pediatrics, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY; and. 6. ICAP at Columbia, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY.
Abstract
BACKGROUND: Prior studies have measured accelerated aging in people with HIV using a DNA methylation (DNAm)-based biomarker of aging, "epigenetic age," but data are limited in African American (AA) young adults with perinatally acquired HIV infection (PHIV). METHODS: We performed a cross-sectional study of AA young adults aged 20-35 years with PHIV (N = 31) and seronegative controls (N = 30) using DNAm measured in whole blood and cognitive function measured by the NIH Toolbox. Illumina EPIC array was used to measure DNAm age and accelerated aging markers including epigenetic age acceleration (EAA), as well as extrinsic (EEAA) and intrinsic (IEAA) EAA. RESULTS: PHIV and controls did not differ by sex (45 vs. 43% male), chronological age (26.2 vs. 28.0 years), or ethnicity. Chronological age and DNAm age were correlated (r = 0.56, P < 0.01). PHIV had a higher mean EAA (2.86 ± 6.5 vs. -2.96 ± 3.9, P < 0.01) and EEAA (4.57 ± 13.0 vs. -4.72 ± 6.0, P < 0.01) than controls; however, IEAA was not different between groups. Among PHIV, EAA and EEAA were higher in those with HIV viral load ≥50 copies/mL than <50 copies/mL (EEA: 8.1 ± 5.2 vs. 0.11 ± 5.5, P = 0 < 0.01 and EEAA: 16.1 ± 10.6 vs. -1.83 ± 9.7, P < 0.01). We observed negative correlations (r = -0.36 to -0.31) between EEAA and executive function, attention, and language scores. CONCLUSIONS: In conclusion, EAA in blood was observed in AA young adults with PHIV on ART using 2 measures, including EEAA which upweights the contribution of immunosenescent cell types. However, there was no evidence of age acceleration with a measure independent of cell type composition.
BACKGROUND: Prior studies have measured accelerated aging in people with HIV using a DNA methylation (DNAm)-based biomarker of aging, "epigenetic age," but data are limited in African American (AA) young adults with perinatally acquired HIV infection (PHIV). METHODS: We performed a cross-sectional study of AA young adults aged 20-35 years with PHIV (N = 31) and seronegative controls (N = 30) using DNAm measured in whole blood and cognitive function measured by the NIH Toolbox. Illumina EPIC array was used to measure DNAm age and accelerated aging markers including epigenetic age acceleration (EAA), as well as extrinsic (EEAA) and intrinsic (IEAA) EAA. RESULTS: PHIV and controls did not differ by sex (45 vs. 43% male), chronological age (26.2 vs. 28.0 years), or ethnicity. Chronological age and DNAm age were correlated (r = 0.56, P < 0.01). PHIV had a higher mean EAA (2.86 ± 6.5 vs. -2.96 ± 3.9, P < 0.01) and EEAA (4.57 ± 13.0 vs. -4.72 ± 6.0, P < 0.01) than controls; however, IEAA was not different between groups. Among PHIV, EAA and EEAA were higher in those with HIV viral load ≥50 copies/mL than <50 copies/mL (EEA: 8.1 ± 5.2 vs. 0.11 ± 5.5, P = 0 < 0.01 and EEAA: 16.1 ± 10.6 vs. -1.83 ± 9.7, P < 0.01). We observed negative correlations (r = -0.36 to -0.31) between EEAA and executive function, attention, and language scores. CONCLUSIONS: In conclusion, EAA in blood was observed in AA young adults with PHIV on ART using 2 measures, including EEAA which upweights the contribution of immunosenescent cell types. However, there was no evidence of age acceleration with a measure independent of cell type composition.
Authors: Andrew M Gross; Philipp A Jaeger; Jason F Kreisberg; Katherine Licon; Kristen L Jepsen; Mahdieh Khosroheidari; Brenda M Morsey; Susan Swindells; Hui Shen; Cherie T Ng; Ken Flagg; Daniel Chen; Kang Zhang; Howard S Fox; Trey Ideker Journal: Mol Cell Date: 2016-04-21 Impact factor: 17.970
Authors: Richard C Gershon; Molly V Wagster; Hugh C Hendrie; Nathan A Fox; Karon F Cook; Cindy J Nowinski Journal: Neurology Date: 2013-03-12 Impact factor: 9.910
Authors: Nicole Phillips; Taryn Amos; Caroline Kuo; Jacqueline Hoare; Jonathan Ipser; Kevin G F Thomas; Dan J Stein Journal: Pediatrics Date: 2016-10-11 Impact factor: 7.124
Authors: John S Manavalan; Stephen Arpadi; Shenthuraan Tharmarajah; Jayesh Shah; Chiyuan A Zhang; Marc Foca; Natalie Neu; David L Bell; Kyle K Nishiyama; Stavroula Kousteni; Michael T Yin Journal: J Bone Miner Res Date: 2016-07-06 Impact factor: 6.741
Authors: Riccardo E Marioni; Sonia Shah; Allan F McRae; Stuart J Ritchie; Graciela Muniz-Terrera; Sarah E Harris; Jude Gibson; Paul Redmond; Simon R Cox; Alison Pattie; Janie Corley; Adele Taylor; Lee Murphy; John M Starr; Steve Horvath; Peter M Visscher; Naomi R Wray; Ian J Deary Journal: Int J Epidemiol Date: 2015-01-22 Impact factor: 7.196
Authors: Salman M Tajuddin; Dena G Hernandez; Brian H Chen; Nicole Noren Hooten; Nicolle A Mode; Mike A Nalls; Andrew B Singleton; Ngozi Ejiogu; Kumaraswamy Naidu Chitrala; Alan B Zonderman; Michele K Evans Journal: Clin Epigenetics Date: 2019-08-19 Impact factor: 6.551
Authors: Mary E Sehl; Tammy M Rickabaugh; Roger Shih; Otoniel Martinez-Maza; Steve Horvath; Christina M Ramirez; Beth D Jamieson Journal: Pathog Immun Date: 2020-10-22
Authors: Stephanie Shiau; Stephen M Arpadi; Yanhan Shen; Anyelina Cantos; Christian Vivar Ramon; Jayesh Shah; Grace Jang; Jennifer J Manly; Adam M Brickman; Andrea A Baccarelli; Michael T Yin Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 20.999